Rejuvenate Bio develops gene therapies aimed at extending healthy lifespan and treating chronic, age-associated diseases by combining advances in gene delivery, translational biology, and longevity science. The company has built a pipeline targeting clinically validated gene targets with a delivery approach designed for well-tolerated, durable expression. Rejuvenate Bio is developing therapies for companion animals with the stated goal of translating insights toward human health applications. The company was founded on research from the Wyss Institute at Harvard Medical School and is headquartered in San Diego, CA. Following the announced $6 million financing, Rejuvenate Bio has also entered a strategic R&D collaboration with Merck Animal Health to advance a targeted animal-health gene therapy program.

Total raised

$10M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2026